KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Common Equity (2016 - 2025)

Pacific Biosciences Of California has reported Common Equity over the past 16 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Common Equity at $5.3 million for Q4 2025, down 98.94% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (down 98.94% YoY), and the annual figure for FY2025 was $5.3 million, down 98.94%.
  • Common Equity for Q4 2025 was $5.3 million at Pacific Biosciences Of California, down from $36.1 million in the prior quarter.
  • Over the last five years, Common Equity for PACB hit a ceiling of $791.0 million in Q4 2021 and a floor of $5.3 million in Q4 2025.
  • Median Common Equity over the past 5 years was $562.9 million (2022), compared with a mean of $475.3 million.
  • Biggest five-year swings in Common Equity: skyrocketed 523.9% in 2021 and later plummeted 98.94% in 2025.
  • Pacific Biosciences Of California's Common Equity stood at $791.0 million in 2021, then decreased by 28.84% to $562.9 million in 2022, then increased by 24.59% to $701.3 million in 2023, then dropped by 27.76% to $506.6 million in 2024, then plummeted by 98.94% to $5.3 million in 2025.
  • The last three reported values for Common Equity were $5.3 million (Q4 2025), $36.1 million (Q3 2025), and $61.5 million (Q2 2025) per Business Quant data.